We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NRR)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00246753
First Posted: October 31, 2005
Last Update Posted: June 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
October 28, 2005
October 31, 2005
March 8, 2017
June 28, 2017
June 28, 2017
October 2005
July 2012   (Final data collection date for primary outcome measure)
Number of Patients Experiencing Decline in Prostate-specific Antigen [ Time Frame: 4 years ]
Determine the number of patients with hormone-refractory prostate cancer who experience > 50% decline in PSA from baseline for 2 successive measurements at least 4 weeks apart after treatment with lapatinib ditosylate.
- To determine the proportion of patients with early hormone refractory prostate cancer experiencing greater than 50% decline in prostate-specific antigen (PSA) after treatment with GW572016.
Complete list of historical versions of study NCT00246753 on ClinicalTrials.gov Archive Site
  • Time to Prostate-Specific Antigen (PSA) Progression [ Time Frame: 4 years ]
    Measured from start date of treatment to date of PSA progression, defined as a 25% increase above the pretreatment value or the nadir PSA (whichever is lower) and a minimum increase of 5 ng/ml, confirmed 2 or more weeks later.
  • Predictive Molecular Markers of Response to Treatment With Lapatinib (GW572016) [ Time Frame: 4 years ]
    To assess the correlation between expression of molecular markers and patient response to treatment with GW572016
  • - To determine the safety profile of GW572016 in this patient population.
  • - To determine the time to PSA progression in patients treated with GW572016.
  • - To explore the molecular correlates and predictive biomarkers of response to GW572016.
Not Provided
Not Provided
 
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer

RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.

OBJECTIVES:

Primary

  • Determine the proportion of patients with hormone-refractory prostate cancer who experience > 50% decline in prostate-specific antigen (PSA) after treatment with lapatinib ditosylate.

Secondary

  • Determine the safety of this drug in these patients.
  • Determine the time to PSA progression in patients treated with this drug.
  • Determine the molecular correlates and predictive biomarkers of response in patients treated with this drug.

OUTLINE: This is a multicenter, open-label study.

Patients receive oral lapatinib ditosylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.

Serum samples are collected for biomarker analysis at baseline and every 4 weeks.

After completion of study treatment, patients are followed at 4 weeks.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
Drug: lapatinib ditosylate
1500 mg, daily until disease progression
Other Name: GW572016
Single Arm Trial
Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
Intervention: Drug: lapatinib ditosylate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
May 2013
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have histologically confirmed diagnosis of adenocarcinoma of the prostate.
  • On androgen deprivation therapy for prostate cancer (either bilateral orchiectomy or medical castration with the testosterone level of <50 ng/dl)
  • Biochemical progression on androgen deprivation therapy with minimum PSA of 5 ng/ml. Progression is defined as two successive rises in PSA, measured at least one week apart. See section 4.1 for additional criteria.
  • Minimum of 4-6 weeks off anti-androgen therapy (4 weeks for flutamide, 6 weeks for bicalutamide and nilutamide).
  • Minimum of 4 weeks off other hormonal therapy (i.e. ketoconazole, megestrol acetate, aminoglutethimide)
  • Minimum of 4 weeks from any prior radiation therapy, surgery, chemotherapy or other investigational agent.
  • Patients must discontinue use of any herbal supplements prior to study initiation.
  • No prior or concurrent exposure to cytotoxic chemotherapy.
  • Age > 18 years.
  • Life expectancy greater than 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or multigated acquisition scan (MUGA) scan.
  • Men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation since the effects of GW572016 on the developing human fetus at the recommended therapeutic dose are unknown.
  • Ability to swallow and retain oral medication.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who have had prior treatment with ErbB family targeting therapies.
  • Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Prior chemotherapy for prostate cancer
  • Patients with known brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to GW572016.
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • A history of a positive HIV test in the past.
  • Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
  • Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (please refer to section 3.2.2 for a list of medications).
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00246753
LCCC 0505
CDR0000550151 ( Other Identifier: PDQ number )
Yes
Not Provided
Not Provided
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline
Principal Investigator: Young Whang, MD, PhD UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top